Iovance Biotherapeutics (IOVA) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Iovance Biotherapeutics published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Iovance's gross margin figure (about 60% in Q3 2026) excludes depreciation and amortization, by its own definition.
• The year-ago quarter included $5.1 million of restructuring charges; Q3 2026 had none.

Source: Iovance Biotherapeutics Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Iovance Biotherapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Iovance Biotherapeutics's Amtagvi revenue was $102 million in Q3 2026, up 77% from $57.5 million in Q3 2025, 84% of total revenue.
• Iovance Biotherapeutics's Proleukin revenue was $19.9 million in Q3 2026, up 99% from $10.0 million in Q3 2025, 16% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Iovance Biotherapeutics said:

“Iovance remains on track towards achieving its guidance range of $410 to $420 million in total product revenue in 2026.”

“Improvements in gross margin are expected to continue, excluding occasional one-time items.”

Source: Iovance Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the IOVA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and net loss per share (basic and diluted), each as first reported in that quarter's release.

We do not hold a confirmed date for Iovance Biotherapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Iovance Biotherapeutics sells two products. Amtagvi (lifileucel), its tumor infiltrating lymphocyte (TIL) therapy for previously treated advanced melanoma, brought in $101.6 million in Q3 2026, up 77%, and Proleukin, an interleukin-2 product, brought in $19.9 million, up 99%. Total net revenue was $121.5 million, up 80% from $67.5 million. (Iovance Form 10-Q, Q3 2026, Nov 5, 2026; Iovance Q3 2026 release, Nov 5, 2026)

Iovance said the $54.0 million increase came from more Amtagvi infusions, a corresponding increase in Proleukin sales, and price increases for both products. Amtagvi revenue is recognized at patient infusion, while Proleukin revenue is recognized on shipment or delivery, so Amtagvi infusions are expected to lag the related Proleukin sales. (Iovance Form 10-Q, Q3 2026, Nov 5, 2026)

Nearly all revenue is in the United States: $120.0 million in Q3 2026, against $1.5 million from the rest of the world, which is Proleukin sold primarily into European markets. No customer reached 10% of gross revenue. Amtagvi is given at authorized treatment centers, a network Iovance put at more than 100 U.S., Canadian and Australian centers, with at least 110 expected to be active by the end of 2026. (Iovance Form 10-Q, Q3 2026, Nov 5, 2026; Iovance Q3 2026 release, Nov 5, 2026)

Iovance's gross margin, which excludes depreciation and amortization, was about 60%, against 56% in Q2 2026, which it put down to higher Amtagvi volume and cost programs. Cost of sales rose $9.6 million, or 25%, including a $2.4 million increase in royalties payable on higher Proleukin sales. (Iovance Q3 2026 release, Nov 5, 2026; Iovance Form 10-Q, Q3 2026, Nov 5, 2026)

Iovance Biotherapeutics reports GAAP results only, with no adjusted EPS. Its net loss narrowed to $22.3 million, or $0.05 per share, from $91.3 million, or $0.25 per share, in Q3 2025, as revenue grew and research and development expense fell $25.8 million, or 34%, to $49.3 million. The year-ago quarter also carried $5.1 million of restructuring charges. (Iovance Q3 2026 release, Nov 5, 2026; Iovance Form 10-Q, Q3 2026, Nov 5, 2026)

Share issuance has raised Iovance's share count. Weighted average shares were 455,919 thousand, against 364,037 thousand a year earlier, and in Q3 2026 Iovance sold 8,666,654 shares under its 2025 sale agreement for about $87.9 million of net proceeds, at a weighted average price of $10.34, which completed that agreement. Stock-based compensation was $11.8 million. (Iovance Q3 2026 release, Nov 5, 2026; Iovance Form 10-Q, Q3 2026, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Iovance Biotherapeutics gives a full-year revenue range in its release. In Q3 2026 it said it remains on track for total product revenue of $410 to $420 million in 2026 and expects gross margin improvements to continue, excluding occasional one-time items. It gives no EPS outlook. (Iovance Q3 2026 release, Nov 5, 2026)

The release lists Iovance's next regulatory steps for Amtagvi: potential approvals in the United Kingdom and Switzerland by 1Q27, a planned submission in Brazil in 2027, and a European Medicines Agency resubmission on track for 2027. A supplemental BLA for lifileucel in non-small cell lung cancer, based on IOV-LUN-202 Cohorts 1 and 2, is planned in 2027. Iovance had about $382 million of cash and investments and expects it to fund operations well into 2029. (Iovance Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Iovance Biotherapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Iovance Biotherapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning IOVA is on is IOVA a buy or a sell?, what analysts expect next is on the IOVA forecast, and what the company does is on the Iovance Biotherapeutics (IOVA) stock page.

Every number on this page can be traced to a document Iovance Biotherapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.